Filing Flows › Prime Medicine (PRME) › Q4 2024
Prime Medicine (PRME) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Feb 28, 2025
Prime Medicine (PRME) reported revenue of $2.2M for the fourth quarter 2024 (Q4 2024) and +944% from the quarter before.
Prime Medicine, Q4 2024: revenue $2.2M, net loss $42.3M, operating cash flow $16.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.2M | +944% | — |
| Operating profit | −$44.2M | — | — |
| Net earnings | −$42.3M | — | — |
| Operating cash flow | $16.2M | — | — |
| Free cash flow | $14.5M | — | — |
What changed
Revenue was $2.2M in Q4 2024, up 944% from the previous quarter.
Operating costs exceeded revenue by $44.2M, an operating margin of -2025.7%. The quarter ended with a net loss of $42.3M, narrower than the previous quarter's $52.5M loss.
Operating cash flow was $16.2M. Non-cash charges added back $1.7M of depreciation and amortization and $5.9M of share-based compensation. Working capital and other items added $50.9M. Capital expenditures of $1.8M left free cash flow of $14.5M.
Questions
What was Prime Medicine's revenue in the fourth quarter 2024?
Prime Medicine (PRME) reported revenue of $2.2M for the fourth quarter 2024 (Q4 2024) and +944% from the quarter before.
Source: Prime Medicine 10-K on SEC EDGAR.